Immunovaccine Inc. develops cancer immunotherapies and infectious disease vaccines based on the Company’s DepoVax(TM) platform, a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase 1 human clinical trials and is currently conducting a Phase 2 study with its lead cancer vaccine therapy, DPX-Survivac, in recurrent lymphoma. DPX-Survivac is expected to enter additional Phase 2 clinical studies in ovarian cancer and glioblastoma (brain cancer). The Company is also advancing an infectious disease pipeline including innovative vaccines for respiratory syncytial virus (RSV) and anthrax.
This impressive collection of assets positions Immunovaccine with an advantageous growth strategy that leverages the unique attributes of DepoVax™ through the development of high-value internal vaccine candidates balanced with the upside of collaborative program advancement.
Contact Immunovaccine Inc.:
1344 Summer Street
Halifax, Nova Scotia, Canada
Telephone: (902) 492-1819
Facsimile: (902) 492-0888
For general inquiries, please contact: email@example.com or (902) 492-1819.
For investor relations & media inquiries, please contact Kimberly Stephens at firstname.lastname@example.org or (902) 492-1819, ext. 1.
For partnering & business development inquiries, please contact Frederic Ors at (902) 492-1819, ext. 4 email@example.com.